Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $34

RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $32 to $34.

byBenzinga Newsdesk

December 21, 2021

1 minute read

RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $32 to $34.

Morgan Stanley Maintains Underweight on Consolidated Edison, Raises Price Target to $75

By Benzinga Newsdesk

March 22, 8:58 AM

Morgan Stanley maintains Consolidated Edison (NYSE:ED) with a Underweight and raises the price target from $71 to $75.

Recap: Tupperware Brands Q4 Earnings

By Benzinga Insights

February 23, 8:52 AM

Tupperware Brands (NYSE:TUP) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

TUP

FDA Approves Sanofi’s Hemophilia A Therapy Offering Significant Bleed Protection

By Vandana Singh

February 24, 10:21 AM

SNY

Why Compass Point Is Initiating Coverage On Marathon Digital, Riot Blockchain

By Priya Nigam

June 21, 4:01 PM

While the blockchain and cryptocurrency space is essentially decentralized, there are some key companies supporting its growth, according to Compass Point. The Crypto Infrastructure Analyst: Michael Del Grosso initiated coverage of the blockchain and cryptocurrency infrastructure. The analyst initiated coverage of:

MARA

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $34

Related Posts

Morgan Stanley Maintains Underweight on Consolidated Edison, Raises Price Target to $75

Recap: Tupperware Brands Q4 Earnings

FDA Approves Sanofi’s Hemophilia A Therapy Offering Significant Bleed Protection

Why Compass Point Is Initiating Coverage On Marathon Digital, Riot Blockchain